Le snus

Presse Medicale

Volumn 41, Issue 1, 2012, Pages 3-9

  Underner, Michel ^a   Perriot, Jean ^b   Peiffer, Gérard ^c  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b Dispensaire Emile Roux   (France)

^c Centre Hospitalier Regional Metz Thionville   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; NITROSAMINE; VARENICLINE;

BRAIN ISCHEMIA; CANCER RISK; CARCINOGENICITY; ESOPHAGUS CANCER; GASTROESOPHAGUS CANCER; HEALTH EDUCATION; HEART INFARCTION; HUMAN; HYPERKERATOSIS; LEUKOPLAKIA; LONG TERM CARE; LUNG CARCINOMA; MOUTH DISEASE; MOUTH LESION; MOUTH MUCOSA; PANCREAS CANCER; PERIODONTAL DISEASE; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; RISK FACTOR; SHORT SURVEY; SMOKELESS TOBACCO; SUBSTITUTION THERAPY; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MOUTH DISEASES; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS; SMOKING; TOBACCO USE DISORDER; TOBACCO, SMOKELESS;

EID: 84855536161     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.06.005     Document Type: Short Survey

References (60)

1. Joossens L. EC oral snuff ban and Sweden. Lancet 1992, 340:57.
2. Dautzenberg B. Le tabac à sucer, cette drôle d'idée que la Suède veut exporter. Inf Respir (Paris) 2010;96.
3. Hu F.B., Hedeker D., Flay B.R., Sussman S., Day L.E., Siddiqui O. The patterns and predictors of smokeless tobacco onset among urban public school teenagers. Am J Prev Med 1996, 12:22-28.
4. Cummings K.M., Michalek A.M., Carl W., Wood R., Haley N.J. Use of smokeless tobacco in a group of professional baseball players. J Behav Med 1989, 12:559-567.
5. Nilsson R. A qualitative and quantitative risk assessment of snuff dipping. Regul Toxicol Pharmacol 1998, 28:1-16.
6. Benowitz N.L., Jacob P., Yu L. Daily use of smokeless tobacco: systemic effects. Ann Intern Med 1989, 111:112-116.
7. Djordjevic M.V., Brunnemann K.D., Hoffmann D. The need for regulation of carcinogenic N-nitrosamines in oral snuff. Food Chem Toxicol 1993, 31:497-501.
8. Kresty L.A., Carmella S.G., Borukhova A., et al. Metabolites of a tobacco-specific nitrosamine, 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone (NNK), in the urine of smokeless tobacco users: relationship between urinary biomarkers and oral leukoplakia. Cancer Epidemiol Biomarkers Prev 1996, 5:521-525.
9. Hatsukami D., Anton D., Keenan R., Callies A. Smokeless tobacco abstinence effects and nicotine gum dose. Psychopharmacology (Berl) 1992, 106:60-66.
10. Post A., Gilljam H., Rosendahl I., Bremberg S., Galanti M.R. Symptoms of nicotine dependence in a cohort of Swedish youths: a comparison between smokers, smokeless tobacco users and dual tobacco users. Addiction 2010, 105:740-746.
11. Henley S.J., Thun M.J., Connell C., Calle E.E. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control 2005, 16:347-358.
12. Winn D.M. Tobacco use and oral disease. J Dent Educ 2001, 65:306-312.
13. Robertson P.B., Walsh M.M., Greene J.C. Oral effects of smokeless tobacco use by professional baseball players. Adv Dent Res 1997, 11:307-312.
14. Poore T.K., Johnson G.K., Reinhardt R.A., Organ C.C. The effects of smokeless tobacco on clinical parameters of inflammation and gingival crevicular fluid prostaglandin E2, interleukin-1alpha, and interleukin-1beta. J Periodontol 1995, 66:177-183.
15. Riley J..3rd, Tomar S.L., Gilbert G.H. Smoking and smokeless tobacco: increased risk for oral pain. J Pain 2004, 5:218-225.
16. Kassab M.M., Cohen R.E. The etiology and prevalence of gingival recession. J Am Dent Assoc 2003, 134:220-225.
17. Andersson G., Björnberg G., Curvall M. Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: a comparative study. J Oral Pathol Med 1994, 23:161-167.
18. Lagrue G., Cormier S., Liger C. Aphtose buccale récidivante après arrêt du tabac. Presse Med 1996, 25:2043.
19. Grady D., Ernster V.L., Stillman L., Greenspan J. Smokeless tobacco use prevents aphthous stomatitis. Oral Surg Oral Med Oral Pathol 1992, 74:463-465.
20. Fisher M.A., Bouquot J.E., Shelton B.J. Assessment of risk factors for oral leukoplakia in West Virginia. Community Dent Oral Epidemiol 2005, 33:45-52.
21. Andersson G., Axéll T., Larsson A. Clinical classification of Swedish snuff dippers' lesions supported by histology. J Oral Pathol Med 1991, 20:253-257.
22. Tomar S.L., Winn D.M., Swango P.A., Giovino G.A., Kleinman D.V. Oral mucosal smokeless tobacco lesions among adolescents in the United States. J Dent Res 1997, 76:1277-1286.
23. Larsson A., Axéll T., Andersson G. Reversibility of snuff dippers' lesion in Swedish moist snuff users: a clinical and histologic follow-up study. J Oral Pathol Med 1991, 20:258-264.
24. Blot W.J., McLaughlin J.K., Winn D.M., et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988, 48:3282-3287.
25. Boffetta P., Hecht S., Gray N., Gupta P., Straif K. Smokeless tobacco and cancer. Lancet Oncol 2008, 9:667-675.
26. Luo J., Ye W., Zendehdel K., et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet 2007, 369:2015-2020.
27. Zendehdel K., Nyrén O., Luo J., et al. Risk of gastroesophageal cancer among smokers and users of Scandinavian moist snuff. Int J Cancer 2008, 122:1095-1099.
28. Alguacil J., Silverman D.T. Smokeless and other noncigarette tobacco use and pancreatic cancer: a case-control study based on direct interviews. Cancer Epidemiol Biomarkers Prev 2004, 13:55-58.
29. Muscat J.E., Stellman S.D., Hoffmann D., Wynder E.L. Smoking and pancreatic cancer in men and women. Cancer Epidemiol Biomarkers Prev 1997, 6:15-19.
30. Slattery M.L., Schumacher M.C., West D.W., Robison L.M. Smoking and bladder cancer. The modifying effect of cigarettes on other factors. Cancer 1988, 61:402-408.
31. Spangler J.G., Michielutte R., Bell R.A., Dignan M.B. Association between smokeless tobacco use and breast cancer among native American women in North Carolina. Ethn Dis 2001, 11:36-43.
32. Bolinder G., Alfredsson L., Englund A., de Faire U. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. Am J Public Health 1994, 84:399-404.
33. Hergens M.P., Alfredsson L., Bolinder G., Lambe M., Pershagen G., Ye W. Long-term use of Swedish moist snuff and the risk of myocardial infarction amongst men. J Intern Med 2007, 262:351-359.
34. Wennberg P., Eliasson M., Hallmans G., Johansson L., Boman K., Jansson J.H. The risk of myocardial infarction and sudden cardiac death amongst snuff users with or without a previous history of smoking. J Intern Med 2007, 262:360-367.
35. Boffetta P., Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ 2009, 339:b3060. 10.1136/bmj.b3060.
36. Hergens M.P., Lambe M., Pershagen G., Terent A., Ye W. Smokeless tobacco and the risk of stroke. Epidemiology 2008, 19:794-799.
37. McPhaul M., Punzi H.A., Sandy A., Borganelli M., Rude R., Kaplan N.M. Snuff-induced hypertension in pheochromocytoma. JAMA 1984, 252:2860-2862.
38. Westman E.C. Does smokeless tobacco cause hypertension?. South Med J 1995, 88:716-720.
39. Bolinder G., de Faire U. Ambulatory 24-hour blood pressure monitoring in healthy, middle-aged smokeless tobacco users, smokers, and nontobacco users. Am J Hypertens 1998, 11:1153-1163.
40. Bolinder G., Norén A., de Faire U., Wahren J. Smokeless tobacco use and atherosclerosis: an ultrasonographic investigation of carotid intima media thickness in healthy middle-aged men. Atherosclerosis 1997, 132:95-103.
41. Wallenfeldt K., Hulthe J., Bokemark L., Wikstrand J., Fagerberg B. Carotid and femoral atherosclerosis, cardiovascular risk factors and C-reactive protein in relation to smokeless tobacco use or smoking in 58-year-old men. J Intern Med 2001, 250:492-501.
42. Tucker L.A. Use of smokeless tobacco, cigarette smoking, and hypercholesterolemia. Am J Public Health 1989, 79:1048-1050.
43. Persson P.G., Carlsson S., Svanström L., Ostenson C.G., Efendic S., Grill V. Cigarette smoking, oral moist snuff use and glucose intolerance. J Intern Med 2000, 248:103-110.
44. Eliasson M., Lundblad D., Hägg E. Cardiovascular risk factors in young snuff users and cigarette smokers. J Intern Med 1991, 230:17-22.
45. Eliasson M., Asplund K., Evrin P.E., Lundblad D. Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA Study. Atherosclerosis 1995, 113:41-53.
46. Subramoney S., Gupta P.C. Anemia in pregnant women who use smokeless tobacco. Nicotine Tob Res 2008, 10:917-920.
47. England L.J., Levine R.J., Mills J.L., Klebanoff M.A., Yu K.F., Cnattingius S. Adverse pregnancy outcomes in snuff users. Am J Obstet Gynecol 2003, 189:939-943.
48. Steyn K., de Wet T., Saloojee Y., Nel H., Yach D. The influence of maternal cigarette smoking, snuff use and passive smoking on pregnancy outcomes: the Birth to Ten Study. Paediatr Perinat Epidemiol 2006, 20:90-99.
49. Pershagen G. Smokeless tobacco. Br Med Bull 1996, 52:50-57.
50. O'Reilly E.J., McCullough M.L., Chao A., et al. Smokeless tobacco use and the risk of Parkinson's disease mortality. Mov Disord 2005, 20:1383-1384.
51. Hatsukami D., Jensen J., Allen S., Grillo M., Bliss R. Effects of behavioral and pharmacological treatment on smokeless tobacco users. J Consult Clin Psychol 1996, 64:153-161.
52. Ebbert J.O., Severson H.H., Croghan I.T., Danaher B.G., Schroeder D.R. A randomized clinical trial of nicotine lozenge for smokeless tobacco use. Nicotine Tob Res 2009, 11:1415-1423.
53. Ebbert J.O., Dale L.C., Patten C.A., et al. Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users. Nicotine Tob Res 2007, 9:43-52.
54. Dale L.C., Ebbert J.O., Glover E.D., et al. Bupropion SR for the treatment of smokeless tobacco use. Drug Alcohol Depend 2007, 90:56-63.
55. Ebbert J.O., Montori V., Vickers K.S., Erwin P.C., Dale L.C., Stead L.F. Interventions for smokeless tobacco use cessation. Cochrane Database Syst Rev 2007, 4. CD004306.
56. Ebbert J.O., Croghan I.T., North F., Schroeder D.R. A pilot study to assess smokeless tobacco use reduction with varenicline. Nicotine Tob Res 2010, 12:1037-1040.
57. Thompson L.E., Barnett J.R., Pearce J.R. Scared straight? Fear appeal antismoking campaigns, risk, self-efficacy and addiction. Health Risk Soc 2009, 11:181-186.
58. Lund K.E., Mc Neill A., Scheffels J. The use of snus for quitting smoking compared with medicinal products. Nicotine Tob Res 2010, 12:817-822.
59. Galanti M.R., Rosendahl I., Wickholm S. The development of tobacco use in adolescence among " snus starters" and " cigarette starters" : an analysis of the Swedish " BROMS" cohort. Nicotine Tob Res 2008, 10:315-323.
60. Connaissances actuelles des effets pour la santé du tabac oral avec attention particulière au snus suédois. Rapport de la Société française de tabacologie pour la Direction générale de la Santé 2008.